{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.049","value":"-14.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"}],"units":"Participants"}],"title":"Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.171","value":"-41.68"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"title":"Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.272","value":"-54.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.953","value":"-65.46"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.802","value":"-67.77"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"85"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.783","value":"-77.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"72"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.838","value":"-77.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"title":"Cycle 23, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.775","value":"-80.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.110","value":"-81.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Cycle 35, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.911","value":"-85.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Cycle 41, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.490","value":"-81.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"title":"Cycle 47, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.561","value":"-76.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Cycle 53, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.677","value":"-64.42"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Cycle 59, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.893","value":"-47.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Cycle 65, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"description":"Bone marrow aspirate and PB samples were collected to characterize the KIT D816V mutation allele fraction. Each cycle is 28 days long.","dispersionType":"Standard Deviation","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEAN","populationDescription":"Safety Population: all participants who received ≥1 dose of avapritinib. Here, 'Number Analyzed' signifies those participants evaluable for this outcome measure at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline up to Month 65","title":"Percent Change From Baseline in V-kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene Homolog Aspartate 816 Valine (KIT D816V) Mutation Burden","type":"SECONDARY","unitOfMeasure":"Percent Change"}